How is TXA2 produced?
Thromboxane A2 is synthesized in the body during the metabolism of arachidonic acid. This process involves the enzyme cyclooxygenase-1 (COX-1). This enzyme isoform is constitutive (physiological), meaning it is constantly expressed in the body and participates in homeostasis regulation.
During the cyclooxygenase pathway, cyclic endoperoxides are formed from arachidonic acid, which are then converted into TXA2. Additionally, in chronic inflammation, thromboxanes, including TXA2, are synthesized by macrophages anchored to the site of injury via fibronectin molecules.
What is the mechanism of action in thrombus formation?
TXA2 is involved in the formation of the primary thrombus (platelet plug). The process occurs in several sequential stages:
- Activation and degranulation — following initial attachment (adhesion) to the damaged surface, platelets become activated. Activated platelets release granule contents, including ADP. Concurrently, they synthesize and release TXA2.
- Positive feedback — the released TXA2 acts on receptors of the platelets themselves and neighboring cells, enhancing their activation and recruiting new cells into the process.
- Intracellular signaling — receptor stimulation leads to an increase in the concentration of calcium ions ($Ca^{2+}$) in the platelet cytoplasm.
- Fibrinogen binding — elevated intracellular calcium levels induce a change in the spatial structure (conformation) of GP IIb/IIIa receptors on the cell membrane. Activated receptors bind to fibrinogen molecules, which form "bridges" between cells, agglutinating them into a single platelet conglomerate (aggregation).
Effect on vascular tone and clinical significance
The pathogenesis of many cardiovascular diseases is based on an imbalance of vasoactive substances. TXA2 is classified among metabolites with significant hypertensive (pressor) action.
TXA2 causes vasoconstriction and is one of the key mediators of functional narrowing (spasm) of the coronary arteries.
Pharmacological regulation
The synthesis of thromboxane A2 can be suppressed using medications that affect hemostasis. The main target in this case is the enzyme cyclooxygenase.
- Acetylsalicylic acid — blocks COX, interrupting the chain of conversion of arachidonic acid into cyclic endoperoxides and subsequently into TXA2.
- NSAIDs (nonsteroidal anti-inflammatory drugs) — block the cyclooxygenase pathway, reducing the production of thromboxane and other prostaglandins.
Class and exam questions
What role does TXA2 play in chronic inflammation?
In chronic inflammation, macrophages fixed in tissues begin to intensely synthesize inflammatory mediators, which are products of arachidonic acid oxidation. One such mediator is TXA2.
How does TXA2 affect GP IIb/IIIa receptors?
TXA2 stimulates specific receptors on the platelet membrane, leading to an increase in intracellular calcium levels. This causes a conformational change in inactive GP IIb/IIIa receptors, enabling them to bind fibrinogen for cell agglutination.
Why does TXA2 cause an increase in blood pressure?
TXA2 belongs to metabolites with pronounced hypertensive (pressor) effects and causes vasoconstriction, i.e., blood vessel narrowing.
What else to study on this topic
- Cyclooxygenase (COX-1 and COX-2)
- Platelet aggregation and GP IIb/IIIa receptors
- Arachidonic acid metabolism
Master the entire topic in the "Physiology" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "TXA2" and 4,128 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 114 video lessons on the subject
Free video lessons: PhysiologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.